Wordt geladen...
Novel Nargenicin A1 Analog Inhibits Angiogenesis by Downregulating the Endothelial VEGF/VEGFR2 Signaling and Tumoral HIF-1α/VEGF Pathway
Targeting angiogenesis is an attractive strategy for the treatment of angiogenesis-related diseases, including cancer. We previously identified 23-demethyl 8,13-deoxynargenicin (compound 9) as a novel nargenicin A1 analog with potential anticancer activity. In this study, we investigated the antiang...
Bewaard in:
| Gepubliceerd in: | Biomedicines |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7460547/ https://ncbi.nlm.nih.gov/pubmed/32751120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8080252 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|